Edgewise Therapeutics Takes Off
Good evening. Welcome to Trends with No Friends.
FOR THOSE JUST JOINING US, HERE’S AN OVERVIEW
Stocks surged. The Nasdaq Composite carried +2.51%. The Russell 2000 rallied +2.10%.
Technology and consumer discretionary gained more than +2.20%. Industrials and basic materials marched more than +1.50%. Real estate, consumer staples and utilities closed negative.
New 52-Week Highs led New Lows — 270 vs. 2.
THE BEST OF THE BEST
Edgewise Therapeutics ($EWTX) is the Best of the Best. The biotech ripped +54.69% following its positive Phase 1 and Phase 2 trial data serving patients with Obstructive Hypertrophic Cardiomyopathy (HCM).
$EWTX closed at its highest price since April 2021.
Here’s the daily chart.
And weekly chart.
THE WORST OF THE WORST
Progyny ($PGNY) is the Worst of the Worst. The fertility benefits management company cratered -32.65% after it disclosed a large client loss.
$PGNY closed at its lowest price since October 2019.
Here’s the daily chart.
And weak weekly chart.
RILEY’S RECS
Report Finds Art Sales Stagnate, Even As The Luxury Sector Continues To Grow
Superconducting Qubit Technology Scales Up Using Industrial Fabrication
Earth Will Get A Second “Mini-Moon” For 2 Months
Switzerland’s Cattle Parade 2024 And Its History
Space Perspective Completes Test Flight Of Its Spaceship That Can Bring Travelers Out Of Earth
GET IN TOUCH
Email me (Riley Rosebee) your feedback; I’d love to hear from you. 📧
Want to sponsor this newsletter and reach thousands of passionate investors and traders? Reach us here. 👍
Terms & Conditions 📝
Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍
Author Disclosure: The author of this newsletter holds positions in SN and LAMR. 📋
